1. Wang X, Ivan M, Hawkins SM. The role of MicroRNA molecules and MicroRNA-regulating machinery in the pathogenesis and progression of epithelial ovarian cancer. Gynecol. Oncol. 2017;147(2):481-7. doi: 10.1016/j.ygyno.2017.08.027

2. Obeagu EI, Obeagu GU. Breast cancer: A review of risk factors and diagnosis. Medicine. 2024;103(3):e36905. doi: 10.1097/MD.0000000000036905

3. Bai J, Jin A, Adams M, Yang C, Nabavi S. Unsupervised feature correlation model to predict breast abnormal variation maps in longitudinal mammograms. CMIG. 2024;113:102341. [DOI:10.1016/j.compmedimag.2024.102341]

4. Melnik I, Rapson Y, Gropstein A, Sharon E. Different approaches to mammography as a screening tool for breast cancer. Harefuah. 2022;161(2):121-4.

5. Oh K, Lee SE, Kim E-K. 3-D breast nodule detection on automated breast ultrasound using faster region-based convolutional neural networks and U-Net. Sci. Rep. 2023;13(1):22625.

6. Wekking D, Porcu M, De Silva P, Saba L, Scartozzi M, Solinas C. Breast MRI: clinical indications, recommendations, and future applications in breast cancer diagnosis. Curr. Oncol. Rep. 2023;25(4):257-67.

7. Goleij P, Babamohamadi M, Rezaee A, Sanaye PM, Tabari MAK, Sadreddini S, et al. Types of RNA therapeutics. PMBTS. 2024;203:41-63. doi: 10.3389/fonc.2024.1385632

8. Iorio MV, Croce CM. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol. Med. 2012;4(3):143-59. doi.org/10.1002/emmm.201100209

9. Stahlhut C, Slack FJ. MicroRNAs and the cancer phenotype: profiling, signatures and clinical implications. Genome Med. 2013;5:1-12.

10. Nana‐Sinkam S, Croce C. Clinical applications for microRNAs in cancer. Clin Pharmacol Ther. 2013;93(1):98-104. doi.org/10.1038/clpt.2012.192

11. Sharma GN, Dave R, Sanadya J, Sharma P, Sharma K. Various types and management of breast cancer: an overview.J. adv. pharm. technol res. 2010;1(2):109-26.

12. Weigelt B, Geyer FC, Reis-Filho JS. Histological types of breast cancer: how special are they? Mol. Oncol. 2010;4(3):192-208. [DOI:10.1016/j.molonc.2010.04.004]

13. Cammaerts S, Strazisar M, De Rijk P, Del Favero J. Genetic variants in microRNA genes: impact on microRNA expression, function, and disease. Front. genet. 2015;6:186. [DOI:10.3389/fgene.2015.00186]

14. Cheng Y, Shang X, Chen D, Pang D, Zhao C, Xu X. MicroRNA‐2355‐5p regulates γ‐globin expression in human erythroid cells by inhibiting KLF6. Br. J. Haematol. 2021;193(2):401-5. [DOI:10.1111/bjh.17134]

15. Connerty P, Ahadi A, Hutvagner G. RNA binding proteins in the miRNA pathway. Int. J. Mol. Sci. 2015;17(1):31.doi. 10.3390/ijms17010031

16. Treiber T, Treiber N, Meister G. Regulation of microRNA biogenesis and its crosstalk with other cellular pathways. Nat. Rev. Mol. Cell Biol. 2019;20(1):5-20.

17. De Palma FDE, Salvatore F, Pol JG, Kroemer G, Maiuri MC. Circular RNAs as potential biomarkers in breast cancer. Biomedicines. 2022;10(3):725.doi. 10.3390/biomedicines10030725

18. He Y, Deng F, Yang S, Wang D, Chen X, Zhong S, et al. Exosomal microRNA: a novel biomarker for breast cancer. Biomark med. 2018;12(2):177-88. [DOI:10.2217/bmm-2017-0305]

19. Hannafon BN, Trigoso YD, Calloway CL, Zhao YD, Lum DH, Welm AL, et al. Plasma exosome microRNAs are indicative of breast cancer. BCR. 2016;18:1-14.

20. Zografos E, Zagouri F, Kalapanida D, Zakopoulou R, Kyriazoglou A, Apostolidou K, et al. Prognostic role of microRNAs in breast cancer: A systematic review. Oncotarget. 2019;10(67):7156. doi: 10.18632/oncotarget.27327

21. Turk MA, Chung CZ, Manni E, Zukowski SA, Engineer A, Badakhshi Y, et al. MiRAR—miRNA activity reporter for living cells. Genes. 2018;9(6):305.doi. 10.3390/genes9060305

22. Uematsu T. Rethinking screening mammography in Japan: next-generation breast cancer screening through breast awareness and supplemental ultrasonography. Breast Cancer. 2024;31(1):24-30.

23. Valencia OM, Samuel SE, Viscusi RK, Riall TS, Neumayer LA, Aziz H. The role of genetic testing in patients with breast cancer: a review. JAMA surgery. 2017;152(6):589-94. doi:10.1001/jamasurg.2017.0552

24. Zou R, Loke SY, Tang YC, Too H-P, Zhou L, Lee AS, et al. Development and validation of a circulating microRNA panel for the early detection of breast cancer. Br. J. Cancer. 2022;126(3):472-81.

25. Yerukala Sathipati S, Ho S-Y. Identifying a miRNA signature for predicting the stage of breast cancer. Sci. Rep. 2018;8(1):16138.

26. Hemmatzadeh M, Mohammadi H, Jadidi-Niaragh F, Asghari F, Yousefi M. The role of oncomirs in the pathogenesis and treatment of breast cancer. Biomed Pharmacother. 2016;78:129-39. [DOI:10.1016/j.biopha.2016.01.026]

27. Curtaz CJ, Schmitt C, Blecharz-Lang KG, Roewer N, Wöckel A, Burek M. Circulating MicroRNAs and blood-brain-barrier function in breast cancer metastasis. "Curr. Pharm. Des. 2020;26(13):1417-27. [DOI:10.2174/1381612826666200316151720]

28. Asghari F, Haghnavaz N, Baradaran B, Hemmatzadeh M, Kazemi T. Tumor suppressor microRNAs: Targeted molecules and signaling pathways in breast cancer. Biomed Pharmacother. 2016;81:305-17. [DOI:10.1016/j.biopha.2016.04.011]

29. Zhang M, Guo W, Qian J, Wang B. Negative regulation of CDC42 expression and cell cycle progression by miR-29a in breast cancer. Open Med. 2016;11(1):78-82. [DOI:10.1515/med-2016-0015]

30. Ghafouri-Fard S, Shoorei H, Anamag FT, Taheri M. The role of non-coding RNAs in controlling cell cycle related proteins in cancer cells. Front. oncol. 2020;10:608975. [DOI:10.3389/fonc.2020.608975]

31. Zhou E, Hui N, Shu M, Wu B, Zhou J. Systematic analysis of the p53‑related microRNAs in breast cancer revealing their essential roles in the cell cycle. Oncol. Lett. 2015;10(6):3488-94. [DOI:10.3892/ol.2015.3751]

32. Yahya SM, Elsayed GH. A summary for molecular regulations of miRNAs in breast cancer. Clin. Biochem. 2015;48(6):388-96. [DOI:10.1016/j.clinbiochem.2014.12.013]

33. Peng X, Yan B, Shen Y. MiR-1301-3p inhibits human breast cancer cell proliferation by regulating cell cycle progression and apoptosis through directly targeting ICT1. Breast Cancer. 2018;25:742-52.

34. Muñoz JP, Pérez-Moreno P, Pérez Y, Calaf GM. The role of MicroRNAs in breast cancer and the challenges of their clinical application. Diagnostics. 2023;13(19):3072.doi. 10.3390/diagnostics13193072

35. Anwar SL, Lehmann U. MicroRNAs: emerging novel clinical biomarkers for hepatocellular carcinomas. J clin med. 2015;4(8):1631-50. doi.10.3390/jcm4081631

36. Amorim M, Salta S, Henrique R, Jerónimo C. Decoding the usefulness of non-coding RNAs as breast cancer markers. J. Transl. Med. 2016;14(1):265.

37. Bellassai N, D'Agata R, Jungbluth V, Spoto G. Surface plasmon resonance for biomarker detection: advances in non-invasive cancer diagnosis. Front. Chem. 2019;7:570.

38. Vlasov V, EIu R, Ponomareva A, Zaporozhchenko I, Morozkin E, Cherdyntseva N, et al. Circulating microRNAs in lung cancer: prospects for diagnostics, prognosis and prediction of antitumor treatment efficiency. Mol. Biol. 2015;49(1):55-66.

39. Pessôa-Pereira D, Evangelista AF, Causin RL, da Costa Vieira RA, Abrahão-Machado LF, Santana IVV, et al. miRNA expression profiling of hereditary breast tumors from BRCA1-and BRCA2-germline mutation carriers in Brazil. BMC cancer. 2020;20:1-10.

40. Di Leva G, Cheung DG, Croce CM. miRNA clusters as therapeutic targets for hormone-resistant breast cancer. Expert Rev Endocrinol Metab. 2015;10(6):607-17. [DOI:10.1586/17446651.2015.1099430]

41. Gahlawat AW, Fahed L, Witte T, Schott S. Total circulating microRNA level as an independent prognostic marker for risk stratification in breast cancer. Br. J. Cancer. 2022;127(1):156-62.

42. Jiang S, Wu J, Geng Y, Zhang Y, Wang Y, Wu J, et al. Identification of Differentially Expressed microRNAs Associated with Ischemic Stroke by Integrated Bioinformatics Approaches. Int. J. Genom. 2022;2022(1):9264555. [DOI:10.1155/2022/9264555]

43. Kleivi Sahlberg K, Bottai G, Naume B, Burwinkel B, Calin GA, Børresen-Dale A-L, et al. A serum microRNA signature predicts tumor relapse and survival in triple-negative breast cancer patients. Cli cancer res. 2015;21(5):1207-14.

44. Pu M, Chen J, Tao Z, Miao L, Qi X, Wang Y, et al. Regulatory network of miRNA on its target: coordination between transcriptional and post-transcriptional regulation of gene expression. Cell. Mol. Life Sci. 2019;76:441-51.

45. Banwait JK, Bastola DR. Contribution of bioinformatics prediction in microRNA-based cancer therapeutics. Adv. Drug Deliv. Rev. 2015;81:94-103. [DOI:10.1016/j.addr.2014.10.030]

46. Faraji G, Moeini P, Ranjbar MH. Exosomal microRNAs in breast cancer and their potential in diagnosis, prognosis and treatment prediction. Pathol. Res. Pract. 2022;238:154081. [DOI:10.1016/j.prp.2022.154081]

47. Gozdowska R, Makowska A, Gąsecka A, Chabior A, Marchel M. Circulating microRNA in Heart Failure—Practical Guidebook to Clinical Application. Cardiol Rev. 2022;30(1):16-23. doi: 10.1097/CRD.0000000000000352

48. Li J, Che Z, Wan X, Manshaii F, Xu J, Chen J. Biomaterials and bioelectronics for self-powered neurostimulation. Biomaterials. 2023:122421